BioCentury
ARTICLE | Company News

AbbVie snubs Galapagos, takes own JAK-1 into Phase III

September 25, 2015 11:46 PM UTC

AbbVie Inc. (NYSE:ABBV) declined to exercise its option to license Janus kinase-1 (JAK-1) inhibitor filgotinib ( GLPG0634) from Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) and said it would begin Phase III testing by YE15 on ABT-494, its own selective JAK-1 inhibitor to treat rheumatoid arthritis (RA).

Galapagos lost EUR 10.32 (19%) to EUR 44.75 on Euronext on Friday, and shed $16.66 (27%) to $44.82 on NASDAQ. AbbVie dipped $0.83 to $55.74. ...